Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more
Market Cap & Net Worth: Kyongbo Pharmaceutical Co Ltd (214390)
Kyongbo Pharmaceutical Co Ltd (KO:214390) has a market capitalization of $116.42 Million (₩170.46 Billion) as of March 19, 2026. Listed on the KO stock exchange, this Korea-based company holds position #21768 globally and #1055 in its home market, demonstrating a 32.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kyongbo Pharmaceutical Co Ltd's stock price ₩7130.00 by its total outstanding shares 23906860 (23.91 Million).
Kyongbo Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Kyongbo Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $211.89 Million to $116.42 Million (-5.43% CAGR).
Kyongbo Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kyongbo Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Kyongbo Pharmaceutical Co Ltd's market cap is 0.00 times its annual revenue
1.00x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.02x
Kyongbo Pharmaceutical Co Ltd's market cap is 0.02 times its annual earnings
9.89x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $211.89 Million | $178.03 Billion | $26.11 Billion | 0.00x | 0.01x |
| 2016 | $211.23 Million | $186.73 Billion | $12.71 Billion | 0.00x | 0.02x |
| 2017 | $193.89 Million | $191.66 Billion | $17.96 Billion | 0.00x | 0.01x |
| 2018 | $161.59 Million | $201.34 Billion | $13.12 Billion | 0.00x | 0.01x |
| 2019 | $131.83 Million | $191.71 Billion | $5.29 Billion | 0.00x | 0.02x |
| 2020 | $262.62 Million | $215.29 Billion | $9.40 Billion | 0.00x | 0.03x |
| 2021 | $173.49 Million | $170.66 Billion | -$7.50 Billion | 0.00x | N/A |
| 2022 | $162.30 Million | $196.26 Billion | $610.59 Million | 0.00x | 0.27x |
| 2023 | $136.99 Million | $216.36 Billion | $2.97 Billion | 0.00x | 0.05x |
| 2024 | $101.56 Million | $238.56 Billion | $4.64 Billion | 0.00x | 0.02x |
Competitor Companies of 214390 by Market Capitalization
Companies near Kyongbo Pharmaceutical Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Kyongbo Pharmaceutical Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Kyongbo Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Kyongbo Pharmaceutical Co Ltd's market cap moved from $211.89 Million to $ 116.42 Million, with a yearly change of -5.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩116.42 Million | +23.57% |
| 2025 | ₩94.21 Million | -7.23% |
| 2024 | ₩101.56 Million | -25.86% |
| 2023 | ₩136.99 Million | -15.60% |
| 2022 | ₩162.30 Million | -6.45% |
| 2021 | ₩173.49 Million | -33.94% |
| 2020 | ₩262.62 Million | +99.21% |
| 2019 | ₩131.83 Million | -18.42% |
| 2018 | ₩161.59 Million | -16.66% |
| 2017 | ₩193.89 Million | -8.21% |
| 2016 | ₩211.23 Million | -0.31% |
| 2015 | ₩211.89 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Kyongbo Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $116.42 Million USD |
| MoneyControl | $116.42 Million USD |
| MarketWatch | $116.42 Million USD |
| marketcap.company | $116.42 Million USD |
| Reuters | $116.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.